Immunotherapy in Prostate Cancer
| dc.contributor.author | Bolat, Deniz | |
| dc.contributor.author | Haydaroğlu, Ayfer | |
| dc.date.accessioned | 2020-12-01T12:36:58Z | |
| dc.date.available | 2020-12-01T12:36:58Z | |
| dc.date.issued | 2019 | |
| dc.department | Ege Üniversitesi | en_US |
| dc.description.abstract | In recent years, immunotherapy has become an important treatment alternative in the treatment of many cancers. Research on immunotherapy in prostate cancer has been accelerated by obtaining Food and Drug Administration (FDA) approval of sipuleucel-T for asymptomatic or minimal symptomatic metastatic castration-resistant prostate cancer (CRPC). Despite all these developments, the patients in whom these agents should be used, sequential use and combination strategies remain unclear. in this review, mechanisms of action and survival outcomes of different immunotherapeutic agents and therapeutic cancer vaccines in mCRPC are discussed. | en_US |
| dc.identifier.doi | 10.4274/uob.galenos.2018.1142 | |
| dc.identifier.endpage | 72 | en_US |
| dc.identifier.issn | 2147-2122 | |
| dc.identifier.issn | 2147-2270 | |
| dc.identifier.issue | 2 | en_US |
| dc.identifier.startpage | 67 | en_US |
| dc.identifier.uri | https://doi.org/10.4274/uob.galenos.2018.1142 | |
| dc.identifier.uri | https://app.trdizin.gov.tr//makale/TXpZNE1qRXdNQT09 | |
| dc.identifier.uri | https://hdl.handle.net/11454/67069 | |
| dc.identifier.volume | 18 | en_US |
| dc.indekslendigikaynak | TR-Dizin | en_US |
| dc.language.iso | en | en_US |
| dc.relation.ispartof | Üroonkoloji Bülteni | en_US |
| dc.relation.publicationcategory | Makale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | 0-Belirlenecek | en_US |
| dc.title | Immunotherapy in Prostate Cancer | en_US |
| dc.type | Article | en_US |
